Stock Track | Beam Therapeutics Plummets 5% as Barclays Slashes Price Target

Stock Track

Aug 06, 2025

Shares of Beam Therapeutics, Inc. (NASDAQ: BEAM) plunged 5.08% in pre-market trading on Wednesday following a bearish analyst report. The sharp decline comes as Barclays lowered its price target for the biotechnology company, signaling potential challenges ahead for the gene-editing specialist.

Barclays, a prominent financial services firm, cut its target price for Beam Therapeutics to $21 from the previous $25. This significant reduction in price target suggests that the investment bank has become more cautious about the company's near-term prospects. The downward revision could be attributed to various factors, including the competitive landscape in the gene-editing sector, potential regulatory hurdles, or concerns about the company's pipeline progress.

The market's strong reaction to this target price cut highlights the sensitivity of biotechnology stocks to analyst opinions, especially for companies like Beam Therapeutics that are still in the development stage. Investors will be closely watching for any further updates from the company or additional analyst commentary to gauge the long-term implications of this price target reduction on Beam's stock performance and its gene-editing technology platform.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1119253960"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1119253960\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1119253960?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-06 21:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119253960","market":"sg","top_or_hot":-1,"title":"Stock Track | Beam Therapeutics Plummets 5% as Barclays Slashes Price Target","media":"Stock Track","content":"<p>Shares of Beam Therapeutics, Inc. (NASDAQ: BEAM) plunged 5.08% in pre-market trading on Wednesday following a bearish analyst report. The sharp decline comes as Barclays lowered its price target for the biotechnology company, signaling potential challenges ahead for the gene-editing specialist.</p>\n\n<p>Barclays, a prominent financial services firm, cut its target price for Beam Therapeutics to $21 from the previous $25. This significant reduction in price target suggests that the investment bank has become more cautious about the company's near-term prospects. The downward revision could be attributed to various factors, including the competitive landscape in the gene-editing sector, potential regulatory hurdles, or concerns about the company's pipeline progress.</p>\n\n<p>The market's strong reaction to this target price cut highlights the sensitivity of biotechnology stocks to analyst opinions, especially for companies like Beam Therapeutics that are still in the development stage. Investors will be closely watching for any further updates from the company or additional analyst commentary to gauge the long-term implications of this price target reduction on Beam's stock performance and its gene-editing technology platform.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Beam Therapeutics Plummets 5% as Barclays Slashes Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Beam Therapeutics Plummets 5% as Barclays Slashes Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-06 21:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Beam Therapeutics, Inc. (NASDAQ: BEAM) plunged 5.08% in pre-market trading on Wednesday following a bearish analyst report. The sharp decline comes as Barclays lowered its price target for the biotechnology company, signaling potential challenges ahead for the gene-editing specialist.</p>\n\n<p>Barclays, a prominent financial services firm, cut its target price for Beam Therapeutics to $21 from the previous $25. This significant reduction in price target suggests that the investment bank has become more cautious about the company's near-term prospects. The downward revision could be attributed to various factors, including the competitive landscape in the gene-editing sector, potential regulatory hurdles, or concerns about the company's pipeline progress.</p>\n\n<p>The market's strong reaction to this target price cut highlights the sensitivity of biotechnology stocks to analyst opinions, especially for companies like Beam Therapeutics that are still in the development stage. Investors will be closely watching for any further updates from the company or additional analyst commentary to gauge the long-term implications of this price target reduction on Beam's stock performance and its gene-editing technology platform.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BEAM","symbol_name":"Beam Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1119253960","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119253960","pubTimestamp":1754488613,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Beam Therapeutics, Inc. (NASDAQ: BEAM) plunged 5.08% in pre-market trading on Wednesday following a bearish analyst report. The sharp decline comes as Barclays lowered its price target for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BEAM":"Beam Therapeutics, Inc."},"translate_title":"股票追踪|巴克莱下调目标价Beam Therapeutics暴跌5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BEAM":1},"content_text":"Shares of Beam Therapeutics, Inc. (NASDAQ: BEAM) plunged 5.08% in pre-market trading on Wednesday following a bearish analyst report. The sharp decline comes as Barclays lowered its price target for the biotechnology company, signaling potential challenges ahead for the gene-editing specialist.\nBarclays, a prominent financial services firm, cut its target price for Beam Therapeutics to $21 from the previous $25. This significant reduction in price target suggests that the investment bank has become more cautious about the company's near-term prospects. The downward revision could be attributed to various factors, including the competitive landscape in the gene-editing sector, potential regulatory hurdles, or concerns about the company's pipeline progress.\nThe market's strong reaction to this target price cut highlights the sensitivity of biotechnology stocks to analyst opinions, especially for companies like Beam Therapeutics that are still in the development stage. Investors will be closely watching for any further updates from the company or additional analyst commentary to gauge the long-term implications of this price target reduction on Beam's stock performance and its gene-editing technology platform.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}